Live Breaking News & Updates on Claritas Pharmaceuticals Inc

Stay updated with breaking news from Claritas pharmaceuticals inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Claritas Pharmaceuticals (OTCMKTS:KALTF) Stock Passes Below Two Hundred Day Moving Average of $0.02

Claritas Pharmaceuticals, Inc. (OTCMKTS:KALTF – Get Rating)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.02 and traded as low as $0.00. Claritas Pharmaceuticals shares last traded at $0.00, with a volume of 0 shares traded. Claritas Pharmaceuticals Stock Performance The company’s […] ....

News Ratings For Claritas Pharmaceuticals Daily , Claritas Pharmaceuticals , Claritas Pharmaceuticals Inc , Claritas Pharmaceuticals Stock Performance , Get Rating , Seth Yakatan , San Rafael , Claritas Pharmaceuticals Daily , Otcmkts Kaltf ,

Claritas Pharmaceuticals (OTCMKTS:KALTF) Share Price Passes Above Fifty Day Moving Average of $0.12

Claritas Pharmaceuticals, Inc. (OTCMKTS:KALTF – Get Rating)’s share price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.12 and traded as high as $0.14. Claritas Pharmaceuticals shares last traded at $0.14, with a volume of 3,440 shares traded. The business has a […] ....

Claritas Pharmaceuticals Inc , Claritas Pharmaceuticals Company Profile , Claritas Pharmaceuticals , Get Rating , Pharmaceuticals Company Profile , Seth Yakatan , San Rafael , Otcmkts Kaltf ,

Claritas Announces Approval from OTC to Up-List to OTCQB

SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 Claritas Pharmaceuticals, Inc. is pleased to announce that it has obtained approval from the OTC Markets Group for listing of its Common. | April 7, 2022 ....

Robert Farrell , Exchange Commission , Claritas Pharmaceuticals Inc , Company Or Claritas , Claritas Pharmaceuticals , Globenewswire Inc , Common Shares , Although Claritas , Claritas Pharmaceuticals Stock Exchange , Press Release , Ts Kly Ca1806341071 ,

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

South Korea , United States , Robert Farrell , Rho Gtpase , Acta Biomater , Company Or Claritas , Claritas Pharmaceuticals , Salzman Group Ltd , Salzman Group , Claritas Pharmaceuticals Inc , Salzman Group Inc , Venture Exchange , Salzman Group Pty , Regulation Services Provider , Orphan Drug Designation , Clinical Study , Wound Healing , Skin Ulcers , Wound Healing Indications , Skin Ulcer , Wound Healing Indication , Nitrogen Species Releasing Hydrogel , Enhanced Wound Healing , Annu Int Conf , Med Biol , Oxide Releasing Hyaluronic Acid ,

Claritas Completes Acquisition of Exclusive Worldwide

Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the Disease. ....

United States , South Korea , Robert Farrell , Company Or Claritas , Claritas Pharmaceuticals , Salzman Group To Claritas , Salzman Group Inc , Salzman Group , Claritas Pharmaceuticals Inc , Salzman Group Ltd , Venture Exchange , Salzman Group Pty , Clarita Development Plan , License Amendment , Nitric Oxide Releasing , License Agreement , Will Develop , Nitric Oxide Therapy , Clarita President , Positive Data , Validated Animal Model , Disease Progression , Near Total Relief , Acute Symptoms , Potential Cure , Safety Profile ,